What is Metagenomi's operating income?

Metagenomi's total operating income in 2025 was -$96.01 million, based on the following breakdown: Total Gross Profit: $25.21 million Total Operating Expenses: $121.22 million

Metagenomi (MGX) Financials

$1.24 -0.05 (-3.88%)

Closing price 07/16/2026 04:00 PM Eastern

Extended Trading

$1.24 0.00 (0.00%)

As of 07/16/2026 06:56 PM Eastern

Compare

Annual Income Statements for Metagenomi

This table shows Metagenomi's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2023	2024	2025
Period end date	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-68	-78	-88
Consolidated Net Income / (Loss)	-68	-78	-88
Net Income / (Loss) Continuing Operations	-68	-78	-88
Total Pre-Tax Income	-60	-84	-88
Total Operating Income	-78	-89	-96
Total Gross Profit	45	52	25
Total Revenue	45	52	25
Operating Revenue	45	52	25
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	123	141	121
Selling, General & Admin Expense	29	32	27
Research & Development Expense	94	109	94
Total Other Income / (Expense), net	18	5.33	8.09
Interest & Investment Income	15	15	9.47
Other Income / (Expense), net	2.80	-9.39	-1.38
Income Tax Expense	8.03	-5.51	-0.06
Basic Earnings per Share	($20.05)	($2.36)	($2.36)
Weighted Average Basic Shares Outstanding	3.40M	33.03M	37.25M
Diluted Earnings per Share	($20.05)	($2.36)	($2.36)
Weighted Average Diluted Shares Outstanding	3.40M	33.03M	37.25M
Weighted Average Basic & Diluted Shares Outstanding	-	37.38M	37.62M

This table shows Metagenomi's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-20	-24	-25	-11	-19	-23	-25	-20	-20	-23	-23
Consolidated Net Income / (Loss)	-20	-19	-25	-11	-19	-23	-25	-20	-20	-23	-23
Net Income / (Loss) Continuing Operations	-20	-24	-25	-11	-19	-23	-25	-20	-20	-23	-23
Total Pre-Tax Income	-19	-17	-25	-13	-21	-25	-25	-20	-21	-22	-23
Total Operating Income	-22	-20	-29	-17	-22	-21	-28	-21	-23	-24	-25
Total Gross Profit	12	12	11	20	12	9.61	4.13	8.51	8.66	3.91	1.25
Total Revenue	12	12	11	20	12	9.61	4.13	8.51	8.66	3.91	1.25
Operating Revenue	12	12	11	20	12	9.61	4.13	8.51	8.66	3.91	1.25
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Operating Expenses	35	33	40	37	34	30	32	30	31	28	26
Selling, General & Admin Expense	7.92	7.84	8.75	8.55	7.64	7.07	6.81	6.99	6.22	6.78	6.54
Research & Development Expense	27	25	31	28	26	23	25	23	25	22	19
Total Other Income / (Expense), net	3.78	3.63	3.88	3.93	1.50	-3.98	2.88	1.12	2.21	1.87	1.54
Interest & Investment Income	3.87	3.63	3.93	3.98	3.62	3.20	2.89	2.49	2.21	1.88	1.54
Other Income / (Expense), net	-0.09	-0.00	-0.05	-0.05	-2.11	-7.18	-0.01	-1.36	-0.00	-0.01	-0.00
Income Tax Expense	1.21	7.12	0.00	-2.20	-2.11	-1.21	0.10	0.04	-0.23	0.03	0.01
Basic Earnings per Share	($5.82)	($5.67)	($1.19)	($0.29)	($0.51)	($0.37)	($0.68)	($0.54)	($0.55)	($0.59)	($0.61)
Weighted Average Basic Shares Outstanding	3.40M	3.40M	21.14M	36.63M	36.77M	33.03M	37.02M	37.16M	37.35M	37.25M	37.58M
Diluted Earnings per Share	($5.82)	($5.67)	($1.19)	($0.29)	($0.51)	($0.37)	($0.68)	($0.54)	($0.55)	($0.59)	($0.61)
Weighted Average Diluted Shares Outstanding	3.40M	3.40M	21.14M	36.63M	36.77M	33.03M	37.02M	37.16M	37.35M	37.25M	37.58M
Weighted Average Basic & Diluted Shares Outstanding	-	0.00	37.46M	37.43M	37.42M	37.38M	37.38M	37.53M	0.00	37.62M	37.65M

This table details how cash moves in and out of Metagenomi's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2023	2024	2025
Period end date	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	-45	-113	14
Net Cash From Operating Activities	-91	-109	-89
Net Cash From Continuing Operating Activities	-91	-110	-89
Net Income / (Loss) Continuing Operations	-68	-78	-88
Consolidated Net Income / (Loss)	-68	-78	-88
Depreciation Expense	4.21	5.41	5.32
Amortization Expense	-9.21	-7.83	-3.21
Non-Cash Adjustments To Reconcile Net Income	9.56	30	18
Changes in Operating Assets and Liabilities, net	-28	-60	-22
Net Cash From Investing Activities	46	-88	104
Net Cash From Continuing Investing Activities	46	-88	104
Purchase of Property, Plant & Equipment	-9.81	-3.11	-0.57
Purchase of Investments	-208	-306	-66
Sale of Property, Plant & Equipment	-	0.00	0.04
Sale and/or Maturity of Investments	264	221	170
Net Cash From Financing Activities	1.01	84	-0.36
Net Cash From Continuing Financing Activities	1.01	84	-0.36
Repayment of Debt	-	0.00	-0.56
Issuance of Preferred Equity	4.30	0.00	0.20
Issuance of Common Equity	0.00	84	0.00
Cash Income Taxes Paid	2.25	3.51	-2.24

This table details how cash moves in and out of Metagenomi's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	50	39	-38	-41	-36	2.27	1.81	-2.35	5.92	8.89	-17
Net Cash From Operating Activities	-24	-21	-30	-26	-27	-26	-23	-21	-21	-24	-21
Net Cash From Continuing Operating Activities	-24	-21	-30	-26	-27	-27	-23	-21	-21	-24	-21
Net Income / (Loss) Continuing Operations	-20	-19	-25	-11	-19	-23	-25	-20	-20	-23	-23
Consolidated Net Income / (Loss)	-20	-19	-25	-11	-19	-23	-25	-20	-20	-23	-23
Depreciation Expense	1.15	1.20	1.27	1.31	1.36	1.46	1.36	1.34	1.32	1.30	1.28
Amortization Expense	-2.46	-1.71	-1.25	-2.06	-3.13	-1.39	-1.01	-0.83	-0.83	-0.47	-0.36
Non-Cash Adjustments To Reconcile Net Income	4.34	3.58	6.19	5.93	6.46	11	2.83	6.09	4.28	3.90	3.89
Changes in Operating Assets and Liabilities, net	-6.94	-4.37	-11	-21	-13	-15	-0.91	-7.94	-5.64	-6.25	-2.92
Net Cash From Investing Activities	76	61	-95	-13	-8.93	29	25	19	27	32	3.99
Net Cash From Continuing Investing Activities	76	61	-95	-13	-8.93	29	25	19	27	32	3.99
Purchase of Property, Plant & Equipment	-2.26	-1.74	-0.92	-0.67	-1.20	-0.33	-0.31	-0.13	-0.07	-0.09	-0.03
Purchase of Investments	-	-39	-175	-75	-45	-12	-22	-19	-6.06	-20	-37
Sale of Property, Plant & Equipment	-	-	-	-	-	-	0.00	-	-	-	0.00
Sale and/or Maturity of Investments	78	101	81	62	37	41	47	38	34	52	41
Net Cash From Financing Activities	-1.91	-1.33	87	-2.03	-0.49	-	-0.08	-0.17	-0.19	0.07	-0.03
Net Cash From Continuing Financing Activities	-1.91	-1.33	87	-2.03	-0.49	-	-0.08	-0.17	-0.19	0.07	-0.03
Repayment of Debt	-	-	0.00	-	-	-	-0.08	-0.28	-0.19	-0.02	-0.03
Issuance of Common Equity	-	-	87	-2.03	-0.49	-	0.00	0.11	-	-0.11	0.00

This table presents Metagenomi's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2023	2024	2025
Period end date	12/31/2023	12/31/2024	12/31/2025
Total Assets	365	325	221
Total Current Assets	278	258	166
Cash & Equivalents	141	27	42
Short-Term Investments	131	221	119
Accounts Receivable	2.45	1.26	0.31
Prepaid Expenses	4.64	8.40	4.43
Plant, Property, & Equipment, net	22	18	12
Total Noncurrent Assets	65	49	43
Long-Term Investments	11	3.45	2.15
Other Noncurrent Operating Assets	54	45	41
Total Liabilities & Shareholders' Equity	365	325	221
Total Liabilities	150	90	63
Total Current Liabilities	69	37	23
Accounts Payable	1.79	0.53	1.49
Accrued Expenses	11	8.42	6.72
Current Deferred Revenue	48	23	8.70
Current Deferred & Payable Income Tax Liabilities	3.27	-	0.00
Other Current Liabilities	4.26	5.59	6.03
Total Noncurrent Liabilities	81	52	40
Noncurrent Deferred Revenue	31	10	2.99
Other Noncurrent Operating Liabilities	50	42	37
Commitments & Contingencies	0.00	0.00	0.00
Redeemable Noncontrolling Interest	351	-	0.00
Total Equity & Noncontrolling Interests	-136	235	159
Total Preferred & Common Equity	-136	235	159
Preferred Stock	0.00	0.00	0.00
Total Common Equity	-136	235	159
Common Stock	9.46	457	469
Retained Earnings	-145	-223	-311
Accumulated Other Comprehensive Income / (Loss)	-0.10	0.71	0.26

This table presents Metagenomi's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	415	386	358	298	272	248	197
Total Current Assets	336	308	282	233	212	190	145
Cash & Equivalents	103	61	25	29	27	33	25
Short-Term Investments	225	239	249	197	178	151	115
Accounts Receivable	2.08	1.65	0.59	1.01	0.87	0.96	0.00
Prepaid Expenses	6.16	6.01	7.12	6.21	5.82	4.75	4.40
Plant, Property, & Equipment, net	21	21	20	17	15	14	11
Total Noncurrent Assets	59	58	56	48	45	44	41
Long-Term Investments	11	11	11	3.45	2.15	2.15	2.15
Other Noncurrent Operating Assets	48	47	46	45	43	42	39
Total Liabilities & Shareholders' Equity	415	386	358	298	272	248	197
Total Liabilities	140	116	103	85	76	69	59
Total Current Liabilities	71	53	46	40	33	30	22
Accounts Payable	6.84	3.45	3.10	2.67	2.89	1.22	2.40
Accrued Expenses	7.08	11	8.84	6.12	5.92	9.90	4.69
Current Deferred Revenue	48	33	29	26	19	13	9.31
Current Deferred & Payable Income Tax Liabilities	3.27	0.00	0.00	0.00	0.00	0.00	0.00
Other Current Liabilities	5.22	5.40	4.70	5.60	5.51	5.57	6.11
Total Noncurrent Liabilities	69	64	57	45	43	40	37
Noncurrent Deferred Revenue	20	17	12	4.37	3.55	1.90	1.64
Other Noncurrent Operating Liabilities	49	46	44	41	40	38	35
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	276	269	256	213	196	178	138
Total Preferred & Common Equity	276	269	256	213	196	178	138
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	276	269	256	213	196	178	138
Common Stock	446	451	454	460	463	466	472
Retained Earnings	-170	-181	-200	-248	-268	-288	-334
Accumulated Other Comprehensive Income / (Loss)	-0.28	-0.27	1.64	0.62	0.37	0.37	-0.04

This table displays calculated financial ratios and metrics derived from Metagenomi's official financial filings.

Metric	2023	2024	2025
Period end date	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	0.00	37,423,917.00	0.00
DEI Adjusted Shares Outstanding	0.00	37,423,917.00	0.00
DEI Earnings Per Adjusted Shares Outstanding	0.00	-2.09	0.00
Growth Metrics	-	-	-
Revenue Growth	0.00%	16.84%	-51.79%
EBITDA Growth	0.00%	-24.80%	5.39%
EBIT Growth	0.00%	-29.85%	0.91%
NOPAT Growth	0.00%	-13.26%	-8.00%
Net Income Growth	0.00%	-14.36%	-12.57%
EPS Growth	0.00%	88.23%	0.00%
Operating Cash Flow Growth	0.00%	-19.32%	18.50%
Free Cash Flow Firm Growth	0.00%	0.00%	28.81%
Invested Capital Growth	0.00%	74.66%	74.21%
Revenue Q/Q Growth	0.00%	-5.06%	-18.45%
EBITDA Q/Q Growth	0.00%	-7.50%	4.20%
EBIT Q/Q Growth	0.00%	-8.38%	3.40%
NOPAT Q/Q Growth	0.00%	-0.48%	-4.06%
Net Income Q/Q Growth	0.00%	-5.55%	0.98%
EPS Q/Q Growth	0.00%	69.19%	-10.28%
Operating Cash Flow Q/Q Growth	0.00%	-5.50%	2.98%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	7.44%
Invested Capital Q/Q Growth	0.00%	42.51%	44.29%
Profitability Metrics	-	-	-
Gross Margin	100.00%	100.00%	100.00%
EBITDA Margin	-180.32%	-192.59%	-377.99%
Operating Margin	-175.38%	-170.00%	-380.85%
EBIT Margin	-169.13%	-187.96%	-386.34%
Profit (Net Income) Margin	-152.50%	-149.26%	-348.54%
Tax Burden Percent	113.33%	93.40%	99.93%
Interest Burden Percent	79.57%	85.02%	90.28%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	-31.72%	-34.69%	-44.67%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-20.75%	-28.51%	-35.70%
Return on Assets (ROA)	-18.71%	-22.64%	-32.20%
Return on Common Equity (ROCE)	19.99%	-7.65%	-44.67%
Return on Equity Simple (ROE_SIMPLE)	50.34%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-55	-62	-67
NOPAT Margin	-122.76%	-119.00%	-266.60%
Net Nonoperating Expense Percent (NNEP)	-4.72%	-5.93%	-9.96%
Return On Investment Capital (ROIC_SIMPLE)	40.52%	-26.50%	-42.38%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	64.45%	61.22%	106.27%
R&D to Revenue	210.93%	208.78%	374.59%
Operating Expenses to Revenue	275.38%	270.00%	480.85%
Earnings before Interest and Taxes (EBIT)	-76	-98	-97
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-81	-101	-95
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	0.00	0.58	0.38
Price to Tangible Book Value (P/TBV)	0.00	0.58	0.38
Price to Revenue (P/Rev)	2.09	2.58	2.41
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	3.63	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-1.31	-1.19	-1.05
Leverage Ratio	1.70	1.53	1.39
Compound Leverage Factor	1.35	1.30	1.25
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	163.01%	0.00%	0.00%
Common Equity to Total Capital	-63.01%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	-0.05	-0.08	-1.95
Noncontrolling Interest Sharing Ratio	163.01%	77.94%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	4.04	6.91	7.22
Quick Ratio	3.97	6.69	7.03
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-112	-80
Operating Cash Flow to CapEx	-931.41%	-3,502.67%	-16,553.45%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.12	0.15	0.09
Accounts Receivable Turnover	18.26	28.21	32.28
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	2.08	2.66	1.68
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	19.99	12.94	11.31
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	19.99	12.94	11.31
Capital & Investment Metrics	-	-	-
Invested Capital	-67	-17	-4.36
Invested Capital Turnover	-0.67	-1.25	-2.37
Increase / (Decrease) in Invested Capital	0.00	50	13
Enterprise Value (EV)	163	-117	-102
Market Capitalization	94	135	61
Book Value per Share	($39.82)	$6.28	$4.26
Tangible Book Value per Share	($39.82)	$6.28	$4.26
Total Capital	215	235	159
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-282	-252	-163
Capital Expenditures (CapEx)	9.81	3.11	0.54
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-62	-28	-18
Debt-free Net Working Capital (DFNWC)	209	221	143
Net Working Capital (NWC)	209	221	143
Net Nonoperating Expense (NNE)	13	16	21
Net Nonoperating Obligations (NNO)	-282	-252	-163
Total Depreciation and Amortization (D&A)	-5.01	-2.42	2.11
Debt-free, Cash-free Net Working Capital to Revenue	-138.02%	-52.88%	-72.17%
Debt-free Net Working Capital to Revenue	467.90%	421.94%	565.67%
Net Working Capital to Revenue	467.90%	421.94%	565.67%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	$0.00	($2.36)	($2.36)
Adjusted Weighted Average Basic Shares Outstanding	0.00	33.03M	37.25M
Adjusted Diluted Earnings per Share	$0.00	($2.36)	($2.36)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	33.03M	37.25M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	37.38M	37.62M
Normalized Net Operating Profit after Tax (NOPAT)	-55	-62	-67
Normalized NOPAT Margin	-122.76%	-119.00%	-266.60%
Pre Tax Income Margin	-134.57%	-159.81%	-348.77%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Metagenomi's official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	0.00	0.00	0.00	37,464,201.00	37,428,994.00	37,423,917.00	37,383,472.00	37,381,495.00	37,533,136.00	0.00	37,620,530.00
DEI Adjusted Shares Outstanding	0.00	0.00	0.00	37,464,201.00	37,428,994.00	37,423,917.00	37,383,472.00	37,381,495.00	37,533,136.00	0.00	37,620,530.00
DEI Earnings Per Adjusted Shares Outstanding	0.00	0.00	0.00	-0.29	-0.50	-0.63	-0.67	-0.53	-0.54	0.00	-0.61
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	28.90%	76.48%	-6.87%	-22.46%	-63.02%	-57.45%	-24.80%	-59.32%	-69.76%
EBITDA Growth	0.00%	0.00%	-50.33%	-4.66%	-10.40%	-33.92%	5.45%	-23.67%	14.91%	15.08%	13.84%
EBIT Growth	0.00%	0.00%	-62.12%	-12.18%	-8.96%	-37.63%	4.31%	-32.13%	6.75%	12.32%	11.64%
NOPAT Growth	0.00%	0.00%	-61.85%	6.12%	0.05%	-2.11%	4.17%	-24.46%	-2.04%	-18.15%	11.62%
Net Income Growth	0.00%	0.00%	-55.88%	17.44%	5.28%	-21.27%	0.43%	-85.38%	-8.63%	3.72%	7.91%
EPS Growth	0.00%	0.00%	74.89%	92.41%	91.24%	93.47%	42.86%	-86.21%	-7.84%	-59.46%	10.29%
Operating Cash Flow Growth	0.00%	0.00%	-42.18%	-0.83%	-12.25%	-27.60%	23.48%	19.23%	20.22%	10.39%	7.30%
Free Cash Flow Firm Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-254.69%	-251.68%	-373.68%	53.92%	54.82%
Invested Capital Growth	0.00%	0.00%	0.00%	0.00%	0.00%	74.66%	73.16%	72.52%	73.39%	74.21%	72.96%
Revenue Q/Q Growth	9.05%	0.29%	-10.00%	79.30%	-42.45%	-16.50%	-57.07%	106.28%	1.72%	-54.83%	-68.09%
EBITDA Q/Q Growth	-40.96%	12.96%	-40.34%	39.22%	-48.70%	-5.59%	0.91%	20.73%	-2.31%	-5.37%	-0.53%
EBIT Q/Q Growth	-49.10%	10.14%	-43.97%	41.84%	-44.82%	-13.50%	-0.09%	19.69%	-2.20%	-6.73%	-0.86%
NOPAT Q/Q Growth	-24.67%	9.82%	-43.75%	41.92%	-32.73%	7.86%	-34.90%	24.56%	-8.82%	-6.69%	-0.90%
Net Income Q/Q Growth	-52.37%	2.65%	-30.34%	57.30%	-74.81%	-24.64%	-7.01%	20.49%	-2.44%	-10.47%	-2.36%
EPS Q/Q Growth	-52.36%	2.58%	79.01%	75.63%	-75.86%	27.45%	-83.78%	20.59%	-1.85%	-7.27%	-3.39%
Operating Cash Flow Q/Q Growth	9.05%	13.22%	-44.96%	11.86%	-1.25%	1.36%	13.07%	6.97%	-0.01%	-10.79%	10.07%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	-30.27%	-53.28%	-568.00%	-1.46%	31.63%	15.70%	21.20%	0.53%
Invested Capital Q/Q Growth	0.00%	0.00%	6.35%	34.06%	28.62%	42.51%	0.82%	32.48%	30.89%	44.29%	-3.99%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-192.42%	-167.01%	-260.42%	-88.27%	-228.10%	-288.43%	-665.79%	-256.57%	-258.08%	-602.10%	-1,896.88%
Operating Margin	-181.15%	-162.88%	-260.17%	-84.28%	-194.40%	-214.51%	-674.10%	-246.53%	-263.76%	-623.04%	-1,970.11%
EBIT Margin	-181.83%	-162.92%	-260.61%	-84.54%	-212.74%	-289.18%	-674.29%	-262.53%	-263.78%	-623.32%	-1,970.19%
Profit (Net Income) Margin	-160.32%	-155.61%	-225.36%	-53.67%	-163.05%	-243.37%	-606.71%	-233.85%	-235.51%	-576.02%	-1,847.68%
Tax Burden Percent	106.48%	116.45%	100.00%	83.00%	89.91%	95.09%	100.39%	100.22%	98.87%	100.15%	100.04%
Interest Burden Percent	82.80%	82.02%	86.47%	76.49%	85.24%	88.50%	89.63%	88.88%	90.31%	92.27%	93.74%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	0.00%	-31.72%	-28.03%	-27.84%	-28.91%	-34.69%	-31.93%	-37.45%	-40.87%	-44.67%	-49.02%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	-19.99%	-29.65%	-12.25%	-32.70%	-43.87%	-85.58%	-26.94%	-26.90%	-57.59%	-177.83%
Return on Assets (ROA)	0.00%	-19.09%	-25.64%	-7.78%	-25.06%	-36.92%	-77.00%	-24.00%	-24.02%	-53.22%	-166.77%
Return on Common Equity (ROCE)	0.00%	19.99%	-28.03%	-27.84%	-28.91%	-7.65%	-31.93%	-37.45%	-40.87%	-44.67%	-49.02%
Return on Equity Simple (ROE_SIMPLE)	0.00%	0.00%	-28.03%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-16	-14	-20	-12	-16	-14	-19	-15	-16	-17	-17
NOPAT Margin	-126.80%	-114.02%	-182.12%	-59.00%	-136.08%	-150.16%	-471.87%	-172.57%	-184.63%	-436.13%	-1,379.08%
Net Nonoperating Expense Percent (NNEP)	0.00%	-1.83%	-2.85%	0.69%	-2.18%	-3.36%	-1.96%	-2.02%	-1.87%	-2.64%	-3.15%
Return On Investment Capital (ROIC_SIMPLE)	-	10.43%	-7.37%	-4.38%	-6.13%	-6.15%	-9.16%	-7.50%	-8.96%	-10.75%	-12.49%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	64.07%	63.23%	78.43%	42.74%	66.36%	73.57%	164.89%	82.15%	71.78%	173.28%	523.64%
R&D to Revenue	217.08%	199.65%	281.74%	141.54%	228.04%	240.94%	609.21%	264.38%	291.99%	549.76%	1,546.47%
Operating Expenses to Revenue	281.15%	262.88%	360.17%	184.28%	294.40%	314.51%	774.10%	346.53%	363.76%	723.04%	2,070.11%
Earnings before Interest and Taxes (EBIT)	-22	-20	-29	-17	-24	-28	-28	-22	-23	-24	-25
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-24	-21	-29	-18	-26	-28	-27	-22	-22	-24	-24
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.24	0.57	0.32	0.58	0.24	0.28	0.50	0.38	0.37
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.24	0.57	0.32	0.58	0.24	0.28	0.50	0.38	0.37
Price to Revenue (P/Rev)	0.00	2.09	1.40	2.73	1.47	2.58	1.12	1.64	2.88	2.41	2.26
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	3.63	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	0.00	-1.31	-1.23	-1.15	-1.11	-1.19	-1.16	-1.11	-1.09	-1.05	-1.06
Leverage Ratio	0.00	1.70	1.51	1.43	1.40	1.53	1.46	1.41	1.40	1.39	1.41
Compound Leverage Factor	0.00	1.39	1.30	1.10	1.19	1.36	1.31	1.26	1.26	1.28	1.32
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	163.01%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	-63.01%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	0.00	0.45	0.36	0.92	0.42	0.64	-0.19	-0.30	-0.26	-0.86	-1.42
Noncontrolling Interest Sharing Ratio	0.00%	163.01%	0.00%	0.00%	0.00%	77.94%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.00	4.04	4.75	5.82	6.18	6.91	5.85	6.36	6.42	7.22	6.43
Quick Ratio	0.00	3.97	4.66	5.71	6.02	6.69	5.69	6.19	6.26	7.03	6.23
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	0.00	42	29	14	-64	-65	-45	-38	-30	-29
Operating Cash Flow to CapEx	-1,050.46%	-1,185.49%	-3,262.30%	-3,956.24%	-2,219.83%	-7,867.07%	-7,344.69%	-16,733.07%	-28,720.27%	-27,701.18%	-84,700.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.12	0.11	0.14	0.15	0.15	0.13	0.10	0.10	0.09	0.09
Accounts Receivable Turnover	0.00	18.26	22.70	33.94	93.51	28.21	29.26	26.79	39.91	32.28	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	2.08	2.25	2.70	2.79	2.66	2.42	1.89	1.84	1.68	1.61
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	19.99	16.08	10.76	3.90	12.94	12.48	13.62	9.14	11.31	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	19.99	16.08	10.76	3.90	12.94	12.48	13.62	9.14	11.31	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	0.00	-67	-62	-41	-29	-17	-17	-11	-7.82	-4.36	-4.53
Invested Capital Turnover	0.00	-0.67	-1.51	-2.72	-3.75	-1.25	-1.14	-1.29	-1.66	-2.37	-2.10
Increase / (Decrease) in Invested Capital	0.00	0.00	-62	-41	-29	50	46	30	22	13	12
Enterprise Value (EV)	0.00	163	-272	-158	-204	-117	-179	-152	-97	-102	-92
Market Capitalization	94	94	66	153	81	135	51	55	89	61	50
Book Value per Share	$0.00	($39.82)	$13.04	$7.19	$6.83	$6.28	$5.69	$5.24	$4.75	$4.26	$3.66
Tangible Book Value per Share	$0.00	($39.82)	$13.04	$7.19	$6.83	$6.28	$5.69	$5.24	$4.75	$4.26	$3.66
Total Capital	0.00	215	276	269	256	235	213	196	178	159	138
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	0.00	-282	-338	-311	-285	-252	-229	-207	-186	-163	-142
Capital Expenditures (CapEx)	2.26	1.74	0.92	0.67	1.20	0.33	0.31	0.13	0.07	0.09	0.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	-62	-62	-45	-38	-28	-33	-27	-24	-18	-18
Debt-free Net Working Capital (DFNWC)	0.00	209	265	255	237	221	193	178	160	143	122
Net Working Capital (NWC)	0.00	209	265	255	237	221	193	178	160	143	122
Net Nonoperating Expense (NNE)	4.14	5.16	4.83	-1.07	3.10	8.96	5.57	5.22	4.41	5.47	5.85
Net Nonoperating Obligations (NNO)	0.00	-282	-338	-311	-285	-252	-229	-207	-186	-163	-142
Total Depreciation and Amortization (D&A)	-1.31	-0.51	0.02	-0.75	-1.77	0.07	0.35	0.51	0.49	0.83	0.92
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-138.02%	-132.17%	-80.73%	-68.97%	-52.88%	-72.17%	-78.70%	-77.24%	-72.17%	-81.07%
Debt-free Net Working Capital to Revenue	0.00%	467.90%	560.63%	455.52%	429.56%	421.94%	427.06%	528.36%	518.35%	565.67%	546.59%
Net Working Capital to Revenue	0.00%	467.90%	560.63%	455.52%	429.56%	421.94%	427.06%	528.36%	518.35%	565.67%	546.59%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	($5.67)	($1.19)	($0.29)	($0.51)	($0.37)	($0.68)	($0.54)	($0.55)	($0.59)	($0.61)
Adjusted Weighted Average Basic Shares Outstanding	0.00	3.40M	21.14M	36.63M	36.77M	33.03M	37.02M	37.16M	37.35M	37.25M	37.58M
Adjusted Diluted Earnings per Share	$0.00	($5.67)	($1.19)	($0.29)	($0.51)	($0.37)	($0.68)	($0.54)	($0.55)	($0.59)	($0.61)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	3.40M	21.14M	36.63M	36.77M	33.03M	37.02M	37.16M	37.35M	37.25M	37.58M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	37.46M	37.43M	37.42M	37.38M	37.38M	37.53M	0.00	37.62M	37.65M
Normalized Net Operating Profit after Tax (NOPAT)	-16	-14	-20	-12	-16	-14	-19	-15	-16	-17	-17
Normalized NOPAT Margin	-126.80%	-114.02%	-182.12%	-59.00%	-136.08%	-150.16%	-471.87%	-172.57%	-184.63%	-436.13%	-1,379.08%
Pre Tax Income Margin	-150.56%	-133.62%	-225.36%	-64.66%	-181.34%	-255.94%	-604.34%	-233.34%	-238.21%	-575.15%	-1,846.88%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Metagenomi Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Metagenomi's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Metagenomi's net income appears to be on an upward trend, with a most recent value of -$87.87 million in 2025, rising from -$68.26 million in 2023. The previous period was -$78.06 million in 2024. Check out Metagenomi's forecast to explore projected trends and price targets.

Metagenomi's total operating income in 2025 was -$96.01 million, based on the following breakdown:

Total Gross Profit: $25.21 million
Total Operating Expenses: $121.22 million

Over the last 2 years, Metagenomi's total revenue changed from $44.76 million in 2023 to $25.21 million in 2025, a change of -43.7%.

Metagenomi's total liabilities were at $62.51 million at the end of 2025, a 30.3% decrease from 2024, and a 58.2% decrease since 2023.

In the past 2 years, Metagenomi's cash and equivalents has ranged from $27.39 million in 2024 to $140.60 million in 2023, and is currently $41.72 million as of their latest financial filing in 2025.

Over the last 2 years, Metagenomi's book value per share changed from -39.82 in 2023 to 4.26 in 2025, a change of -110.7%.

Related Companies

Financial statements for NASDAQ:MGX last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Metagenomi (MGX) Financials

Financials Breakdown Chart

Metagenomi Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Metagenomi (MGX) Financials

Annual Income Statements for Metagenomi

Quarterly Income Statements for Metagenomi

Annual Cash Flow Statements for Metagenomi

Quarterly Cash Flow Statements for Metagenomi

Annual Balance Sheets for Metagenomi

Quarterly Balance Sheets for Metagenomi

Annual Metrics And Ratios for Metagenomi

Quarterly Metrics And Ratios for Metagenomi

Financials Breakdown Chart

Metagenomi Financials - Frequently Asked Questions

When does Metagenomi's fiscal year end?

How has Metagenomi's net income changed over the last 2 years?

What is Metagenomi's operating income?

How has Metagenomi's revenue changed over the last 2 years?

How much debt does Metagenomi have?

How much cash does Metagenomi have?

How has Metagenomi's book value per share changed over the last 2 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools